Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 3 12Phase 1/2 8Phase 2/3 4Phase 1 4Phase 4 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Gallbladder Neoplasms 5Cholangiocarcinoma 5Nasopharyngeal Carcinoma 4Carcinoma, Transitional Cell 4Biliary Tract Neoplasms 4Recurrence 3Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Virus Diseases 1Urethral Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Malignant Tumor of Pancreas Metastatic to Liver 1Liver Neoplasms 1Klatskin Tumor 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Gemcitabine 4Cisplatin 2vinflunine 1valrubicin 1pembrolizumab 1enfortumab vedotin 1cabazitaxel 1XRP6258 1Rogaratinib 1Oncolytic Virotherapy 1Mitomycin 1Interferons 1Drug Therapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma, Transitional Cell × Gemcitabine × Clear all
NCT07129993 2026-05-14

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Daiichi Sankyo

Phase 2/3 Recruiting
630 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Vasgene Therapeutics, Inc

Phase 2/3 Recruiting
700 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT01438112 2021-04-14

BOND

CG Oncology, Inc.

Phase 2/3 Terminated
22 enrolled
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT00389155 2015-12-07

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Bristol-Myers Squibb

Phase 2/3 Completed
34 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡